Get the Stockscreener App
71.11
4.40%
3.00
Pre-market:
69.71
-1.40
-1.97%
Nektar Therapeutics stock is traded at $71.11, with a volume of 1.01M.
It is up +4.40% in the last 24 hours and up +88.92% over the past month.
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
See More
Previous Close:
$68.11
Open:
$69
24h Volume:
1.01M
Relative Volume:
0.92
Market Cap:
$1.99B
Revenue:
$90.12M
Net Income/Loss:
$-276.06M
P/E Ratio:
-48.71
EPS:
-1.46
Net Cash Flow:
$-193.47M
1W Performance:
+1.05%
1M Performance:
+88.92%
6M Performance:
+97.64%
1Y Performance:
+8,327%
1-Day Range:
$68.00
$72.98
1-Week Range:
$64.50
$72.98
52-Week Range:
$0.432
$75.67
Nektar Therapeutics Stock (NKTR) Company Profile
Name
Nektar Therapeutics
Sector
Industry
Phone
(415) 482-5300
Address
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Compare NKTR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
71.11 | 1.91B | 90.12M | -276.06M | -193.47M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-10-26 | Upgrade | William Blair | Mkt Perform → Outperform |
| Nov-26-25 | Initiated | Citigroup | Buy |
| Jun-24-25 | Reiterated | BTIG Research | Buy |
| Jun-24-25 | Reiterated | H.C. Wainwright | Buy |
| Apr-11-25 | Upgrade | Jefferies | Hold → Buy |
| Mar-14-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-08-25 | Initiated | B. Riley Securities | Buy |
| Dec-10-24 | Initiated | H.C. Wainwright | Buy |
| Nov-04-24 | Initiated | Piper Sandler | Overweight |
| Sep-30-24 | Resumed | BTIG Research | Buy |
| Jun-28-24 | Initiated | Rodman & Renshaw | Buy |
| Nov-20-23 | Resumed | JP Morgan | Underweight |
| Nov-09-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| May-10-23 | Upgrade | Jefferies | Underperform → Hold |
| Feb-24-23 | Downgrade | Jefferies | Hold → Underperform |
| Aug-08-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-31-22 | Resumed | Jefferies | Hold |
| Apr-18-22 | Downgrade | Goldman | Neutral → Sell |
| Mar-15-22 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-15-22 | Downgrade | Mizuho | Buy → Neutral |
| Mar-14-22 | Downgrade | BTIG Research | Buy → Neutral |
| Mar-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-14-22 | Downgrade | Stifel | Buy → Hold |
| Mar-14-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-09-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-08-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Sep-10-21 | Initiated | BofA Securities | Neutral |
| Jun-28-21 | Upgrade | Stifel | Hold → Buy |
| May-18-21 | Resumed | Goldman | Neutral |
| Feb-22-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jan-06-21 | Initiated | Stifel | Hold |
| Sep-14-20 | Initiated | JP Morgan | Neutral |
| Jun-10-20 | Downgrade | CFRA | Hold → Sell |
| May-12-20 | Reiterated | H.C. Wainwright | Neutral |
| Apr-22-20 | Initiated | The Benchmark Company | Buy |
| Mar-30-20 | Upgrade | Goldman | Sell → Neutral |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Feb-03-20 | Upgrade | Mizuho | Neutral → Buy |
| Oct-24-19 | Initiated | Oppenheimer | Perform |
| Oct-08-19 | Downgrade | Goldman | Buy → Sell |
| Aug-09-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-09-19 | Downgrade | Jefferies | Buy → Hold |
| Aug-09-19 | Downgrade | Mizuho | Buy → Neutral |
| Mar-15-19 | Initiated | SVB Leerink | Mkt Perform |
| Dec-13-18 | Initiated | Goldman | Buy |
| Jun-11-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-04-18 | Reiterated | H.C. Wainwright | Buy |
| Apr-20-18 | Initiated | Seaport Global Securities | Buy |
| Apr-13-18 | Resumed | Piper Jaffray | Overweight |
| Apr-06-18 | Reiterated | Mizuho | Buy |
| Apr-02-18 | Resumed | H.C. Wainwright | Buy |
View All
Nektar Therapeutics Stock (NKTR) Latest News
Nektar Therapeutics at TD Cowen Conference: Immunology Focus - Investing.com Nigeria
Nektar Therapeutics at TD Cowen Conference: Immunology Focus By Investing.com - Investing.com UK
Nektar Therapeutics (HAM:ITH0) Selling and Marketing Expens - GuruFocus
Assessing Nektar Therapeutics (NKTR) Valuation After New Multiple Sclerosis Collaboration With UCSF - Yahoo Finance
Does Nektar (NKTR)–UCSF MS Collaboration Hint At A Broader Neuroscience Pivot For The Company? - Yahoo Finance
Assessing Nektar Therapeutics (NKTR) Valuation After Recent Share Price Momentum And Undervaluation Narrative - simplywall.st
BTIG Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $151 - 富途牛牛
Erste Asset Management GmbH Takes $1 Million Position in Nektar Therapeutics $NKTR - MarketBeat
Nektar Therapeutics (HAM:ITH0) Accounts Payable : €15.56 Mil (As of Sep. 2025) - GuruFocus
Nektar Therapeutics (HAM:ITH0) Inventories, Work In Process : €0.00 Mil (As of Sep. 2025) - GuruFocus
Nektar Therapeutics (HAM:ITH0) Short-Term Capital Lease Obl - GuruFocus
Nektar Therapeutics (HAM:ITH0) Cash Flow from Others : €-60.04 Mil (TTM As of Sep. 2025) - GuruFocus
Nektar Therapeutics (HAM:ITH0) Stock Price, Trades & News - GuruFocus
Nektar Therapeutics to Participate in Two Investor Conferences in March - Sahm
Nektar Therapeutics Stock Historical Valuations - GuruFocus
Nektar Therapeutics (HAM:ITH0) Return-on-Tangible-Equity : -466.82% (As of Sep. 2025) - GuruFocus
Nektar Therapeutics (HAM:ITH0) Cyclically Adjusted Book per Share : €0.00 (As of Sep. 2025) - GuruFocus
Nektar Therapeutics (HAM:ITH0) Capex-to-Operating-Cash-Flow : 0.00 (As of Sep. 2025) - GuruFocus
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets - Finviz
United StatesGoodwin Advises Nektar Therapeutics On Its $460 Million Public Offering, Including Full Exercise Of Underwriters' Option To Purchase Additional Shares - Mondaq
Nektar Therapeutics sets March 12 call on 2025 financials - Stock Titan
Nektar Therapeutics MS Collaboration Adds New Angle To Volatile Stock Story - simplywall.st
Wall Street Analysts Think Nektar (NKTR) Could Surge 89.8%: Read This Before Placing a Bet - Finviz
Nektar Therapeutics (NKTR) Price Target Increased by 13.48% to 132.45 - Nasdaq
Nektar Therapeutics to Participate in Two Investor Conferences i - GuruFocus
Wall Street experts predict that Nektar (NKTR) may climb by 89.8%: Consider this information before making an investment decision - Bitget
Back-to-back investor conferences send Nektar to Boston and Miami - Stock Titan
Nektar Therapeutics (NASDAQ:NKTR) Sets New 52-Week HighTime to Buy? - MarketBeat
Nektar Therapeutics stock hits 52-week high at 75.19 USD By Investing.com - Investing.com India
Nektar Therapeutics’ (NKTR) “Buy” Rating Reaffirmed at B. Riley Financial - Defense World
A Look At Nektar Therapeutics (NKTR) Valuation After New UCSF Multiple Sclerosis Collaboration - simplywall.st
Nektar Therapeutics (NKTR) Receives Positive Analyst Rating Upgr - GuruFocus
B. Riley Securities Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Raises Target Price to $150 - 富途牛牛
Nektar Therapeutics stock hits 52-week high at 75.19 USD - Investing.com
B. Riley Raises Price Target on Nektar Therapeutics to $150 From $105, Keeps Buy Rating - marketscreener.com
Rezpegaldesleukin Shows Sustained Benefit in Moderate-to-Severe Atopic Dermatitis in Phase 2 b trial - Medical Dialogues
Jonathan Zalevsky Sells 180 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock - MarketBeat
Howard Robin Sells 423 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock - MarketBeat
What is Nektar Therapeutics’s valuation compared to sectorJuly 2025 Highlights & Weekly Stock Breakout Alerts - mfd.ru
Persistent Asset Partners Ltd Takes $983,000 Position in Nektar Therapeutics $NKTR - MarketBeat
Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight - StreetInsider
Nektar Therapeutics stock pops on $300M equity offering - MSN
UCSF, Nektar team to test potential of antibody therapy for MS - Multiple Sclerosis News Today
Which Is a Better Investment, Liquidia Corporation or Nektar Therapeutics Stock? - AAII.com
Which Is a Better Investment, Amneal Pharmaceuticals, Inc. or Nektar Therapeutics Stock? - AAII
Nektar Therapeutics: Unique MOA Translates To Stellar AD Maintenance Data, Strong Buy - Seeking Alpha
Nektar Therapeutics and UCSF explore TNFR2 agonism in MS - BioWorld MedTech
Nektar Therapeutics (NASDAQ:NKTR) Reaches New 12-Month HighShould You Buy? - MarketBeat
45,042 Shares in Nektar Therapeutics $NKTR Bought by Readystate Asset Management LP - MarketBeat
Nektar Therapeutics Announces Research Collaboration with University of California, San Francisco - marketscreener.com
StockWatch: Nektar’s Rezpeg Sparks a Sweet “Comeback Story” - Genetic Engineering and Biotechnology News
Nektar Therapeutics Stock (NKTR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):